[{"data":1,"prerenderedAt":213},["ShallowReactive",2],{"$f32maei0tteuy":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":53,"top_diseases":80,"top_companies":108,"key_results":132,"trends":202,"previous_editions":211,"comparison":137,"highlighted_classes":212},1,"aaaai-2026","AAAAI","aaaai","AAAAI Annual Meeting 2026",2026,"Immunology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},967,350,76,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":4,"Phase 3":21},6,9,21,8,41,[23,27,30,34,37,41,43,45,47,50],{"name":24,"count":25,"share":26},"IL4R",54,15,{"name":28,"count":29,"share":26},"IL13RA1",53,{"name":31,"count":32,"share":33},"IgE",40,11,{"name":35,"count":36,"share":18},"ADRB2",31,{"name":38,"count":39,"share":40},"ADRA1",26,7,{"name":42,"count":39,"share":40},"ADRA1A",{"name":44,"count":39,"share":40},"ADRA2A",{"name":46,"count":39,"share":40},"ADRB1",{"name":48,"count":49,"share":40},"KLKB1",23,{"name":51,"count":52,"share":17},"KIT",20,[54,58,62,66,69,73,76,78],{"name":55,"count":56,"share":57},"Monoclonal antibodies",152,43,{"name":59,"count":60,"share":61},"Small molecules",134,38,{"name":63,"count":64,"share":65},"Allergen extracts and allergen immunotherapy products",44,13,{"name":67,"count":57,"share":68},"Natural-product mixtures and botanicals",12,{"name":70,"count":71,"share":72},"Non-antibody therapeutic proteins",16,5,{"name":74,"count":33,"share":75},"Oligonucleotide and RNA therapeutics",3,{"name":77,"count":72,"share":4},"Bispecific antibodies",{"name":79,"count":72,"share":4},"Vaccines",[81,84,86,89,92,94,96,99,102,106],{"name":82,"count":83,"share":71},"asthma",56,{"name":85,"count":32,"share":33},"atopic dermatitis (AD)",{"name":87,"count":88,"share":18},"food allergy",33,{"name":90,"count":91,"share":20},"hereditary angioedema (HAE)",27,{"name":93,"count":39,"share":40},"anaphylaxis",{"name":95,"count":39,"share":40},"chronic rhinosinusitis with nasal polyps (CRSwNP)",{"name":97,"count":98,"share":40},"peanut allergy",25,{"name":100,"count":101,"share":17},"chronic idiopathic urticaria (CIU)",22,{"name":103,"count":104,"share":105},"allergic rhinitis (AR)",14,4,{"name":107,"count":65,"share":105},"penicillin allergy",[109,111,114,116,118,120,123,125,128,130],{"name":110,"count":83,"share":71},"Regeneron Pharmaceuticals",{"name":112,"count":113,"share":20},"Genentech",29,{"name":115,"count":91,"share":20},"GSK",{"name":117,"count":39,"share":40},"Sanofi",{"name":119,"count":101,"share":17},"AstraZeneca",{"name":121,"count":122,"share":72},"Aimmune Therapeutics",17,{"name":124,"count":68,"share":75},"Pfizer",{"name":126,"count":20,"share":127},"Blueprint Medicines",2,{"name":129,"count":40,"share":127},"Takeda",{"name":131,"count":17,"share":127},"BioCryst Pharmaceuticals",[133,142,149,155,161,167,175,181,187,195],{"title":134,"drug":135,"company":137,"phase":138,"disease":139,"finding":140,"url":141},"Efficacy of Benralizumab by Organ Involvement in Hypereosinophilic Syndrome (HES): Exploratory Analyses from the NATRON Study",{"name":136,"slug":136},"benralizumab",null,"Phase 3","hypereosinophilic syndrome (HES)","In the primary analysis, benralizumab-treated patients (n=67) experienced a reduced risk of HES flare compared to placebo-treated patients (n=66); HR (95% CI): 0.35 (0.18–0.69); P=0.0024.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.721",{"title":143,"drug":144,"company":137,"phase":138,"disease":146,"finding":147,"url":148},"Dupilumab for Treatment of Allergic Fungal Rhinosinusitis in Adults and Children Aged 6 and Over: Results from LIBERTY-AIMS Study",{"name":145,"slug":145},"dupilumab","allergic fungal rhinosinusitis (AFRS)","The proportion of patients experiencing ≥1 treatment-emergent adverse event was 69.7% with dupilumab vs 78.6% placebo.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.946",{"title":150,"drug":151,"company":137,"phase":138,"disease":85,"finding":153,"url":154},"Rocatinlimab Does Not Impact Vaccination-Induced Immune Responses in Adults With Moderate-to-Severe Atopic Dermatitis: Results From the Phase 3 ROCKET-VOYAGER Trial",{"name":152,"slug":152},"rocatinlimab","Patient incidence of TEAEs (patients receiving at least one dose of study drug; 128 ROCA, 68 PBO): ROCA, 41.4% vs PBO, 30.9%; serious AEs, 2.3% vs 0.0%.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.957",{"title":156,"drug":157,"company":137,"phase":138,"disease":95,"finding":159,"url":160},"Twice-Yearly Depemokimab Improved Nasal Polyp Burden and Nasal Obstruction in Chinese Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Subpopulation Analysis of Phase 3 ANCHOR-1\u002F2 Trials",{"name":158,"slug":158},"depemokimab","In integrated analysis, participants on depemokimab and placebo reported similar incidences of on-treatment adverse events (68% [23\u002F34] vs. 86% [25\u002F29]) and serious adverse events (3% [1\u002F34] vs. 14% [4\u002F29]).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.253",{"title":162,"drug":163,"company":137,"phase":138,"disease":90,"finding":165,"url":166},"Safety and Efficacy of Donidalorsen in Adolescent Patients With Hereditary Angioedema: 1-Year Results From OASISplus",{"name":164,"slug":164},"donidalorsen","Three of four (75%) patients reported TEAEs, none of which were severe, serious, related to donidalorsen, or led to treatment discontinuation.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.065",{"title":168,"drug":169,"company":137,"phase":171,"disease":172,"finding":173,"url":174},"Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Non-Advanced Systemic Mastocytosis",{"name":170,"slug":170},"bezuclastinib","Phase 2","systemic mastocytosis (SM)","At week 24, bezuclastinib led to significantly greater symptom improvement vs placebo (LS mean MS2D2 TSS change: -24.3 vs -15.4; placebo-adjusted difference: -8.9 points; P =0.0002).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.525",{"title":176,"drug":177,"company":137,"phase":171,"disease":85,"finding":179,"url":180},"Rapid Improvement in Skin, Itch, and Sleep: Physician- and Patient-Reported Outcomes from the Phase 2 APEX Study of APG777 in Atopic Dermatitis",{"name":178,"slug":178},"apg777","Significant improvement in itch with APG777 was observed as early as Day 3, with a mean -18.1% change from baseline in I-NRS (vs. -4.2% placebo; p\u003C0.01), which improved through Week 16 (-50.7% vs -23.2%; p=0.001).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.074",{"title":182,"drug":183,"company":137,"phase":171,"disease":100,"finding":185,"url":186},"Initial Results From A Phase 2, Open-label Extension Study To Evaluate The Long-term Safety And Efficacy Of The Anti-KIT Briquilimab Antibody In Adults With Chronic Urticaria",{"name":184,"slug":184},"briquilimab","Briquilimab treatment resulted in durable disease control in CSU patients, with 8 of 11 participants (73%) achieving complete response in UAS7 at the Week 12 assessment.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.079",{"title":188,"drug":189,"company":137,"phase":192,"disease":85,"finding":193,"url":194},"STMC-103H Reduces Risk of Atopic Dermatitis and Food Allergy in At-Risk Infants: Results of the Phase 1b\u002F 2 Randomized, Double-Blind, Placebo-Controlled ADORED Trial",{"name":190,"slug":191},"STMC-103H","stmc-103h","Phase 1\u002F2","Subjects who completed the full year of treatment with STMC-103H demonstrated a 64% reduction in the risk of developing AD compared to placebo (23.3% vs 43.1%; OR = 0.36; 90% CI 0.20-0.66; unadjusted p = 0.005) at D336.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.938",{"title":196,"drug":197,"company":137,"phase":199,"disease":137,"finding":200,"url":201},"Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of BP11 (Omalizumab Biosimilar) Compared To EU-Omalizumab And US-Omalizumab",{"name":198,"slug":198},"omalizumab","Phase 1","Treatment-emergent adverse events (TEAEs) were reported by 63.6%, 73.2% and 90.7% subjects in the BP11, EU-Omalizumab, and US-Omalizumab groups, respectively.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jaci.2025.12.350",{"summary":203,"bullets":205},[204],"Monoclonal antibodies were the most frequent modality (43% of drug-linked abstracts). IL4R was the most frequent target (15%). Asthma was the most frequent disease (16%).",[206,207,208,209,210],"Regeneron Pharmaceuticals had the largest company share (16% of drug-linked abstracts).","Small molecules were the next most frequent modality (38%).","IL13RA1 was the next most frequent target (15%).","Atopic dermatitis (AD) was the next most frequent disease (11%).","Genentech had the next largest company share (8%).",[],[],1793970603085]